After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role as chief executive officer of Paris-based Ipsen, effective July 1.
Cambridge, Massachusetts-based Unum Therapeutics announced a restructuring in order to shift assets toward the company’s preclinical program, BOXR1030, for solid tumors.
Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.
GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.
One is going, one is staying – and getting a promotion.
Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.
FDA Commissioner Scott Gottlieb plans to step down in April 2019, a sudden resignation that calls into question how the regulatory agency will handle issues such as surging e-cigarette use among teens and efforts to increase competition in prescription drugs.
Chief Commercial Officer Steven Hoerter resigned his role at Agios Pharmaceuticals to accept a role as chief executive officer at an oncology-focused biotechnology company.
Morris Plains, N.J.-based Immunomedics announced that the company’s president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.
Shares of Editas Medicine were down nearly 20 percent after CEO Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1, 2019.